- /
- Supported exchanges
- / US
- / TXG.NASDAQ
10X Genomics Inc (TXG NASDAQ) stock market data APIs
10X Genomics Inc Financial Data Overview
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with 10X Genomics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get 10X Genomics Inc data using free add-ons & libraries
Get 10X Genomics Inc Fundamental Data
10X Genomics Inc Fundamental data includes:
- Net Revenue: 619 M
- EBITDA: -26 509 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
10X Genomics Inc News
New
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
10x Genomics TXG announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics (SPDx) will use its Xenium platform in a collaborative breast cancer biomarker study....
10x Genomics (TXG) Could Be 24% Undervalued After Raising Its 2026 Revenue Outlook
10x Genomics (TXG) kicked off November with a busy run of news, capped by third quarter 2026 earnings that combined modest top line progress with a narrower loss and a higher full year revenue outlook...
10x Genomics Launches Sentira AI Tool to Simplify Cell Analysis
10x Genomics TXG recently announced the commercial launch of Sentira Single Cell, a cloud-based agentic AI application designed to simplify the analysis of Chromium single-cell data. Powered by Anthro...
10x Genomics forecasts $625M-$635M 2026 revenue as it targets ~50 Atera shipments by year-end
Earnings Call Insights: 10x Genomics (TXG) Q3 2026 MANAGEMENT VIEW * "Revenue for the third quarter was $151 million, up 1% year-over-year." (CEO Serge Saxonov) "The biggest highlight was the star...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.